Toripalimab, pemetrexed

Phase 2Small molecule

Toripalimab, pemetrexed is one of 17 small molecule programs targeting Leptomeningeal Metastasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leptomeningeal MetastasisActive, not recruiting

Leptomeningeal MetastasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Leptomeningeal Metastasis

#DrugCompanyPhaseTrials

Cytosar

Lenvima

Trexall

Alimta

10 5

Tepadina

Jazz Pharmaceuticals

Phase 2

1 6

Intrathecal Chemotherapy

PPrincess Maxima Center for Pediatric Oncology

Phase 3

1 7

Furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 2

2 8

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Phase 2

1 9

AK112

SSummit Therapeutics

Phase 2

1 10

QL1706

Qilu Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Leptomeningeal Metastasis1 trial

Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors

Active, not recruiting·GGuangzhou Medical University·Phase 1/2·NCT06462222·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Toripalimab, pemetrexed. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Toripalimab, pemetrexed compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Toripalimab, pemetrexed. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGuangzhou Medical University

Toripalimab, pemetrexed

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Leptomeningeal Metastasis1 trial

References

Drug Info

Quick Facts

Related News